Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thalmann

Showing results (241-250 of 307) with videos related to

Pageof 31
Sort By:
Plos One|December 9, 2014
The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell nichesBerna C Özdemir, Janine Hensel, Chiara Secondini, et al.
The Prostate|July 3, 1998
Workgroup 2: human xenograft models of prostate cancerM E Stearns, J L Ware, D B Agus, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 16, 2025
Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug responseJuening Kang, Panagiotis Chouvardas, Andrew Maalouf, et al.
Urologic Oncology|September 14, 2014
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practiceBas W G van Rhijn, James W Catto, Peter J Goebell, et al.
The Journal of Urology|August 19, 2011
Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative studyPascal Zehnder, Urs E Studer, Eila C Skinner, et al.
International Journal of Cancer|February 21, 2009
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapySpasenija Savic, Inti Zlobec, George N Thalmann, et al.
Scientific Reports|February 17, 2017
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapyBernhard Kiss, Alexander W Wyatt, James Douglas, et al.
Cancer Research|May 21, 2013
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progressionNicole Longoni, Manuela Sarti, Domenico Albino, et al.
Frontiers in Cell and Developmental Biology|December 21, 2017
ALK1Fc Suppresses the Human Prostate Cancer Growth in <i>in Vitro</i> and <i>in Vivo</i> Preclinical ModelsLetizia Astrologo, Eugenio Zoni, Sofia Karkampouna, et al.
European Urology|March 29, 2014
Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapyCyrill A Rentsch, Frédéric D Birkhäuser, Claire Biot, et al.
Pageof 31

Showing results (241-250 of 307) with videos related to

Sort By:
Pageof 31
Plos One|December 9, 2014
The molecular signature of the stroma response in prostate cancer-induced osteoblastic bone metastasis highlights expansion of hematopoietic and prostate epithelial stem cell nichesBerna C Özdemir, Janine Hensel, Chiara Secondini, et al.
The Prostate|July 3, 1998
Workgroup 2: human xenograft models of prostate cancerM E Stearns, J L Ware, D B Agus, et al.
Journal of Experimental & Clinical Cancer Research : CR|October 16, 2025
Multi-layer stratified oncology platform utilizing transcriptomics, prostate cancer organoids, and modeling of drug responseJuening Kang, Panagiotis Chouvardas, Andrew Maalouf, et al.
Urologic Oncology|September 14, 2014
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practiceBas W G van Rhijn, James W Catto, Peter J Goebell, et al.
The Journal of Urology|August 19, 2011
Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative studyPascal Zehnder, Urs E Studer, Eila C Skinner, et al.
International Journal of Cancer|February 21, 2009
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapySpasenija Savic, Inti Zlobec, George N Thalmann, et al.
Scientific Reports|February 17, 2017
Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapyBernhard Kiss, Alexander W Wyatt, James Douglas, et al.
Cancer Research|May 21, 2013
ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progressionNicole Longoni, Manuela Sarti, Domenico Albino, et al.
Frontiers in Cell and Developmental Biology|December 21, 2017
ALK1Fc Suppresses the Human Prostate Cancer Growth in <i>in Vitro</i> and <i>in Vivo</i> Preclinical ModelsLetizia Astrologo, Eugenio Zoni, Sofia Karkampouna, et al.
European Urology|March 29, 2014
Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapyCyrill A Rentsch, Frédéric D Birkhäuser, Claire Biot, et al.
Pageof 31